A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Pancreatic Cancer Metastatic

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, Guangdong, China

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

PDAC · PDAC - Pancreatic Ductal Adenocarcinoma · NSCLC

Abroad (travel likely)RecruitingPHASE1, PHASE2

Scottsdale, United States · Denver, United States

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Pancreatic Cancer

Abroad (travel likely)RecruitingPHASE2

Baltimore, United States

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Advanced Solid Tumors With KRAS G12C Mutations · Solid Tumor, Adult · Unresectable Solid Tumor

Abroad (travel likely)RecruitingPHASE1, PHASE2

La Jolla, United States · Orange, United States

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Pancreatic Cancer · PDAC - Pancreatic Ductal Adenocarcinoma · Pancreas Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beijing, China